- Home
- FWDI vs AUTL Comparison
FWDI vs AUTL Comparison
Compare FWDI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FWDI | AUTL |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United Kingdom |
| Employees | 60 | N/A |
| Industry | Plastic Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.2M | 431.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | FWDI | AUTL |
|---|---|---|
| Price | $4.26 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 882.9K | ★ 1.7M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $407.02 | $85.73 |
| Revenue Next Year | N/A | $70.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $4.06 | $1.11 |
| 52 Week High | $9.28 | $2.70 |
Technical Indicators
Market Signals| Indicator | FWDI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 48.12 |
| Support Level | $4.06 | $1.27 |
| Resistance Level | $5.75 | $1.52 |
| Average True Range (ATR) | 0.32 | 0.08 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 10.43 | 66.20 |
Price Performance
Historical ComparisonAbout FWDI Forward Industries Inc.
Forward Industries Inc is a provider of carrying and protective solutions. The company operates in two segments: design and digital assets. The design segment consists of two operating segments (IPS and Kablooe, which have been aggregated into one reportable segment) that provide a full spectrum of hardware and software product design and engineering services to customers predominantly.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.